Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study

Official URL:https://doi.org/10.1200/JCO.2005.02.163
PubMed:View item in PubMed
Creators Name:Thuss-Patience, P.C. and Kretzschmar, A. and Repp, M. and Kingreen, D. and Hennesser, D. and Micheel, S. and Pink, D. and Scholz, C. and Doerken, B. and Reichardt, P.
Journal Title:Journal of Clinical Oncology
Journal Abbreviation:J Clin Oncol
Volume:23
Page Range:494-501
Date:1 January 2005
Keywords:Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Disease Progression, Epirubicin, Fluorouracil, Intravenous Infusions, Stomach Neoplasms, Survival Analysis, Taxoids, Treatment Outcome
Abstract:PURPOSE: A combination of docetaxel and fluorouracil (DF) was evaluated in an outpatient setting and compared with epirubicin, cisplatin, and fluorouracil (ECF), which served as an internal control arm to avoid selection bias. PATIENTS AND METHODS: Patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy were randomly assigned to receive either ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks) or DF (docetaxel 75 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks). RESULTS: Ninety patients were randomly assigned. Toxicity was rarely severe. Major toxic effects included diarrhea, stomatitis, and leukopenia in the DF arm and nausea, vomiting, and leukopenia in the ECF arm. Forty-three of 45 patients in each arm were assessable. In the DF arm, two patients (4.4%, intent to treat) experienced a confirmed complete tumor remission as best response, and 15 patients (33.3%) experienced a confirmed partial remission (overall response rate [ORR], 37.8%; 95% CI, 25.9% to 51.9%). Two patients (4.4%) in the ECF arm showed confirmed complete remission, and 14 (31.1%) showed confirmed partial remission (ORR, 35.6%; 95% CI, 24.8% to 48.7%). For the DF and ECF arms, the median survival was 9.5 and 9.7 months, and the median time to tumor progression 5.5 and 5.3 months, respectively. CONCLUSION: DF can be safely given in an ambulant setting. Compared with ECF, the dual combination of DF shows promising efficacy and may be an alternative treatment option that avoids cisplatin.
ISSN:0732-183X
Item Type:Article

Repository Staff Only: item control page

Open Access
MDC Library